Klaria Pharma Holding AB (publ.) (FRA:6FN)

Market Cap	11.61M
Revenue (ttm)	909.12K
Net Income (ttm)	-4.16M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	9.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	325
Open	0.0406
Previous Close	0.0448
Day's Range	0.0406 - 0.0406
52-Week Range	0.0160 - 0.1470
Beta	n/a
RSI	50.36
Earnings Date	Nov 21, 2025

About FRA:6FN

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FN

Financial Performance

In 2024, FRA:6FN's revenue was 2.25 million, a decrease of -73.41% compared to the previous year's 8.45 million. Losses were -47.75 million, 33.4% more than in 2023.

Financial numbers in SEK